Search

Search Constraints

You searched for: Author/Creator Montanaro, Marco

Search Results

1. Anagrelide in Essential Thrombocythemia (ET): Results from 150 patients over 25 years by the "Ph1‐negative Myeloproliferative Neoplasms Latium Group". (16th June 2020)

2. Azacytidine for the treatment of retrospective analysis from the Gruppo Laziale for the study of Ph-negative MPN. Issue 8 (August 2015)

3. Azacytidine for the treatment of retrospective analysis from the Gruppo Laziale for the study of Ph-negative MPN. Issue 8 (August 2015)

4. Chelation efficacy and erythroid response during deferasirox treatment in patients with myeloproliferative neoplasms in fibrotic phase. (18th September 2015)

5. Deferasirox in the treatment of iron overload during myeloproliferative neoplasms in fibrotic phase: does ferritin decrement matter?. (January 2019)

6. Hemoglobin levels and circulating blasts are two easily evaluable diagnostic parameters highly predictive of leukemic transformation in primary myelofibrosis. Issue 3 (March 2015)

7. High platelet count at diagnosis is a protective factor for thrombosis in patients with essential thrombocythemia. Issue 156 (August 2017)

8. Prognostic factors for thrombosis-free survival and overall survival in polycythemia vera: A retrospective analysis of 623 PTS With long follow-up. (June 2018)

9. Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia. (23rd May 2017)

10. Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: Evaluation on 1, 297 patients. Issue 3 (22nd February 2016)